Chelsea Ma is a Dermatology physician affiliated with University of California, Davis. OpenAlex indexes 28 publications with 805 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 16 Apr 2024.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Organon LLCProgram year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
26.8%Azole Antifungal15.9%Ketoconazole100%Part D≥70 patientsTetracycline-class Drug6.2%Doxycycline Hyclate100%Part D≥23 patients+ 3 more classes in this area
Dermatology
21.1%Interleukin-4 Receptor alpha Antagonist8.6%Dupixent Pen74%Dupixent Syringe26%Part D<11 patientsCorticosteroid8.3%Triamcinolone Acetonide100%Part D≥67 patients+ 2 more classes in this area
Sensory organs
19.6%Corticosteroid19.6%Clobetasol Propionate50%Hydrocortisone40%Desonide11%Part D≥61 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intralesional interleukin‐2 augmentation therapy in treatment‐refractory melanoma
Dermatologic Therapy
2022 - Successful Management of Anti-TNF-Induced Psoriasis Despite Continuation of Therapy in a Pyoderma Gangrenosum Patient
Journal of Drugs in Dermatology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Ezra Amsterdam, MD
University of California, Davis
Michael Rogawski, MD
University of California, Davis
Christopher Bowlus, MD
University of California, Davis
Emanual Maverakis, MD
University of California, Davis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”